Acquired ATTR amyloidosis, also known as wild-type ATTR amyloidosis, is a condition where misshapen protein deposits gradually accumulate in vital organs, especially the heart and nervous system. Treatment strategies focus on slowing the buildup of these harmful proteins, managing symptoms like heart failure and nerve damage, and improving daily quality of life through both established therapies and promising new approaches currently being tested in clinical trials.

Managing a complex protein disorder: what treatment can do for you

When someone receives a diagnosis of acquired ATTR amyloidosis, understanding treatment options becomes a crucial part of their journey. This disease happens when a protein called transthyretin, which normally circulates in the blood to carry thyroid hormones and vitamin A, becomes unstable and folds incorrectly. These misfolded proteins clump together into deposits known as amyloid fibrils, which then accumulate in organs like the heart and nervous system.^[1] Unlike hereditary forms caused by genetic mutations, acquired ATTR amyloidosis (also called wild-type ATTR) develops with age for reasons that medical science has not yet fully explained. It most commonly affects males over 65 years old, though experts believe the condition is significantly underdiagnosed and may be more widespread than current data suggests.^[2]

The main goals of treating acquired ATTR amyloidosis center on preventing or slowing down the formation and deposit of these harmful protein clumps, managing the complications that arise when organs become damaged, and helping patients maintain the best possible quality of life. Treatment plans must be individualized, as the disease manifests differently in each person depending on which organs are most affected and how far the condition has progressed. Some patients primarily experience heart-related symptoms such as shortness of breath, fatigue, and swelling in the ankles and legs, while others may face nerve problems causing numbness, tingling, or pain in their hands and feet.^[2]

Over the past decade, the landscape of ATTR amyloidosis treatment has transformed dramatically. Medical societies now recognize several standard treatments proven effective in clinical practice, and researchers continue to develop innovative therapies through clinical trials. These advances offer hope that wasn’t available to patients even a few years ago. Understanding both the established treatment approaches and the experimental therapies being tested can help patients and their families feel more informed and empowered as they work with their healthcare teams to manage this challenging condition.^[8]

Standard approaches to treating acquired ATTR amyloidosis

The traditional backbone of treatment for acquired ATTR amyloidosis has evolved significantly, though one historical option—liver transplantation—has declined in use since the 1990s thanks to the development of effective medications. Liver transplantation was once considered the gold standard because the liver produces most of the body’s transthyretin protein. By replacing a patient’s liver, doctors could stop the production of abnormal transthyretin at its source. However, this major surgical procedure carries substantial risks and requires lifelong immunosuppression medications to prevent organ rejection. With newer pharmaceutical options now available, far fewer patients undergo liver transplantation for ATTR amyloidosis today.^[6]

Current standard treatment relies primarily on medications that work through two main strategies: stabilizing the transthyretin protein to prevent it from breaking apart and forming amyloid deposits, or reducing the production of transthyretin altogether. For patients with cardiac involvement—when amyloid builds up in the heart—tafamidis represents a major breakthrough. This medication belongs to a class called TTR stabilizers, which work by binding to the transthyretin protein and holding it in its correct shape, preventing it from misfolding and clumping into harmful amyloid fibrils. The U.S. Food and Drug Administration has approved tafamidis specifically for treating ATTR cardiomyopathy (ATTR-CM), where the heart muscle becomes stiff and weak due to amyloid deposits.^[6]

Tafamidis is taken as a daily oral capsule, making it relatively convenient for most patients. Long-term follow-up studies tracking patients for up to nine years suggest that continued treatment with tafamidis may improve survival rates, though individual results vary depending on how advanced the disease is when treatment begins. Patients typically tolerate this medication well, with most side effects being mild. However, like all medications, tafamidis can cause adverse reactions in some people, and doctors monitor patients regularly to ensure the treatment remains safe and beneficial.^[6]

Another TTR stabilizer that has recently received FDA approval is acoramidis, sold under the brand name Attruby. This medication offers an additional option for patients with ATTR-CM and works through a similar mechanism of stabilizing the transthyretin protein to prevent amyloid formation.^[6]

Beyond medications that target the underlying protein problem, standard treatment includes comprehensive management of symptoms and complications. When amyloid deposits damage the heart, patients often develop heart failure, requiring medications to manage fluid buildup and support heart function. Diuretics (often called “water pills”) help remove excess fluid that accumulates in the legs, abdomen, and lungs, making breathing easier and reducing swelling. Doctors must carefully balance diuretic use because too much fluid removal can drop blood pressure dangerously low or strain the kidneys.^[10]

Patients with acquired ATTR amyloidosis may also experience irregular heart rhythms, particularly atrial fibrillation, where the upper chambers of the heart beat chaotically. This condition requires medication to control heart rate and often blood-thinning drugs to prevent blood clots that could cause a stroke. Some patients develop problems with their heart’s electrical system, leading to abnormally slow heart rates that may require implantation of a pacemaker. Managing these cardiac complications requires ongoing monitoring and adjustment of treatments based on how each patient responds.^[2]

When nerve damage occurs, patients may experience pain, numbness, or uncomfortable tingling sensations. Medications used to treat nerve pain in other conditions, such as certain antidepressants or anticonvulsants, can help manage these symptoms in ATTR amyloidosis patients as well. The disease can also affect the autonomic nervous system, which controls automatic body functions like blood pressure regulation, digestion, and bladder control. Treatments for autonomic problems are tailored to specific symptoms—for example, medications to prevent blood pressure from dropping when standing up, or drugs to manage diarrhea or constipation caused by digestive system involvement.^[1]

Supportive care forms a critical component of standard treatment. This includes dietary modifications such as reducing sodium intake to minimize fluid retention, monitoring fluid consumption, and maintaining adequate nutrition despite digestive symptoms. Physical therapy and cardiac rehabilitation programs help patients maintain mobility and cardiovascular fitness safely. Healthcare teams also address the psychological and emotional impacts of living with a chronic, progressive disease through counseling and support groups. Because acquired ATTR amyloidosis affects many aspects of health, successful treatment requires a team approach involving multiple specialists who communicate regularly about a patient’s care.^[8]

Innovative treatments being tested in clinical research

The field of ATTR amyloidosis treatment is experiencing rapid advancement through clinical trials testing novel therapeutic approaches. Unlike standard treatments that stabilize existing transthyretin protein, several promising experimental therapies aim to dramatically reduce the production of transthyretin in the first place. If the liver makes much less of this protein, there’s less raw material available to misfold and form harmful amyloid deposits. This concept has led to the development of medications using cutting-edge genetic technologies.^[6]

One groundbreaking approach involves RNA interference (RNAi), a natural cellular process that researchers have harnessed to silence specific genes. Patisiran, an RNAi medication, uses small pieces of genetic material called siRNA (small interfering RNA) that are packaged in tiny fat particles called lipid nanoparticles. When injected into the bloodstream, these nanoparticles travel to the liver and deliver the siRNA, which then interferes with the messenger RNA that carries instructions for making transthyretin. By blocking this messenger RNA, patisiran prevents liver cells from producing the transthyretin protein. The medication is given through an intravenous infusion every three weeks.^[6]

Patisiran earned FDA approval for treating polyneuropathy (nerve disease) caused by hereditary ATTR amyloidosis based on results from a major clinical trial called APOLLO. In this Phase III study, 148 patients receiving patisiran showed significant improvement in nerve function scores and quality of life measures after 18 months compared to 77 patients who received placebo (inactive treatment). Patients experienced less nerve damage progression and better daily functioning. While patisiran is currently approved for hereditary ATTR, researchers continue studying whether it might benefit patients with acquired ATTR as well, particularly those who have both cardiac and nerve involvement.^[6]

A related RNAi medication called vutrisiran (brand name Amvuttra) offers several advantages over patisiran. Vutrisiran uses similar RNA interference technology but is formulated differently, allowing it to be given as a subcutaneous injection (under the skin) once every three months rather than requiring intravenous infusions. This less frequent dosing and simpler administration method may be more convenient for patients and caregivers. The FDA has approved vutrisiran for treating polyneuropathy in hereditary ATTR amyloidosis, and the agency has recently expanded its approval to include ATTR cardiomyopathy as well, making it one of the few medications approved for cardiac involvement in this disease.^[6]

Another genetic approach uses antisense oligonucleotide technology. Inotersen (Tegsedi) is an antisense drug that works by binding directly to the transthyretin messenger RNA before it can be translated into protein. This binding causes the messenger RNA to be broken down, preventing transthyretin production. Inotersen is administered as a once-weekly subcutaneous injection that patients or caregivers can give at home after proper training. The FDA approved inotersen in 2018 for polyneuropathy in hereditary ATTR amyloidosis. Because this medication can sometimes affect platelet counts (cells that help blood clot) and kidney function, patients require regular blood monitoring to ensure safety.^[6]

A newer antisense medication called eplontersen (Wainua) represents the latest addition to this class of drugs. Eplontersen received FDA approval for treating polyneuropathy caused by hereditary ATTR in adults. This medication uses a more advanced chemical structure designed to enhance effectiveness and potentially reduce side effects compared to earlier antisense drugs. Like inotersen, it’s given as a subcutaneous injection, though researchers continue refining the optimal dosing schedule through ongoing studies.^[6]

Another medication under investigation is diflunisal, a non-steroidal anti-inflammatory drug that has been studied for its ability to stabilize transthyretin. While diflunisal is already approved for treating arthritis and pain, researchers have explored using it for ATTR amyloidosis because laboratory studies showed it could bind to transthyretin and prevent the protein from breaking apart. Some clinical evidence suggests it may slow disease progression in certain patients, though it remains under investigation specifically for amyloidosis treatment and is not formally approved for this use. Patients considering diflunisal must be carefully monitored for side effects common to NSAIDs, including stomach ulcers, kidney problems, and increased bleeding risk.^[6]

Tolcapone has received Orphan Drug designation from the FDA for ATTR amyloidosis treatment, a special status granted to medications being developed for rare diseases. Tolcapone is currently approved for Parkinson’s disease but has shown potential for stabilizing transthyretin in laboratory studies. Orphan Drug designation provides incentives for pharmaceutical companies to continue researching treatments for diseases affecting small patient populations, though the drug still requires clinical trial testing before it could be approved specifically for amyloidosis.^[6]

Clinical trials for ATTR amyloidosis typically progress through three phases. Phase I trials involve small numbers of participants (usually 20-80 people) and focus primarily on safety—determining what doses are tolerable and what side effects occur. Phase II trials enroll more patients (typically 100-300) and begin examining whether the treatment actually works by measuring its effects on disease progression and symptoms. Phase III trials are the largest, often involving thousands of patients, and compare the new treatment directly against current standard treatments or placebo to definitively prove effectiveness and safety. Only after successfully completing Phase III trials can pharmaceutical companies apply for regulatory approval to market a new medication.^[6]

Many clinical trials for ATTR amyloidosis are conducted at specialized medical centers in the United States, Europe, and other regions around the world. Patient eligibility varies by trial but typically depends on factors including the type of ATTR amyloidosis (hereditary versus acquired), which organs are affected, disease severity, and what other medical conditions a patient has. Some trials specifically recruit patients with cardiac involvement, while others focus on those with nerve damage. Patients interested in clinical trial participation should discuss options with their healthcare team and can search for trials through resources like ClinicalTrials.gov or patient advocacy organizations that maintain trial registregistries.^[1]

Most common treatment methods

• Transthyretin stabilizers
  • Tafamidis (Vyndamax) binds to transthyretin protein and prevents it from breaking apart and forming amyloid deposits, approved specifically for ATTR cardiomyopathy and taken as a daily oral capsule
  • Acoramidis (Attruby) is a newer TTR stabilizer also approved for ATTR-CM that works through a similar mechanism of preventing protein misfolding
  • Diflunisal remains under investigation for its stabilizing effects on transthyretin, though it is not formally approved for amyloidosis treatment
• RNA interference therapies
  • Patisiran (Onpattro) uses small interfering RNA packaged in lipid nanoparticles to reduce transthyretin production in the liver, given by intravenous infusion every three weeks
  • Vutrisiran (Amvuttra) employs similar RNA interference technology but is administered as a subcutaneous injection once every three months and has expanded FDA approval for both nerve and cardiac involvement
• Antisense oligonucleotide medications
  • Inotersen (Tegsedi) binds to transthyretin messenger RNA to prevent protein production, given as weekly subcutaneous injections with required monitoring for platelet and kidney function
  • Eplontersen (Wainua) represents a newer-generation antisense drug with potentially improved effectiveness and safety profile, also administered by subcutaneous injection
• Supportive cardiac care
  • Diuretics help manage fluid buildup caused by heart failure, reducing swelling in legs and lungs and improving breathing
  • Medications to control heart rhythm problems such as atrial fibrillation, including rate-control drugs and blood thinners to prevent stroke
  • Pacemaker implantation for patients who develop abnormally slow heart rates due to damage to the heart’s electrical system
• Nerve pain and autonomic symptom management
  • Medications used for neuropathic pain, including certain antidepressants and anticonvulsants, to reduce uncomfortable tingling, burning, or stabbing sensations
  • Treatments for autonomic dysfunction such as medications to prevent blood pressure drops when standing, or drugs to manage digestive symptoms
• Liver transplantation
  • Historically the gold standard treatment, liver transplantation replaces the source of abnormal transthyretin production but has declined in use due to newer pharmaceutical options
  • Reserved for carefully selected patients, typically those with early-stage disease, due to surgical risks and need for lifelong immunosuppression